Evidence map›Paper›PMID 9366575›Full record

ArticleThe Journal of clinical investigation1997

Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture.

Y Imai, W H Busby, C E Smith, J B Clarke, A J Garmong, G D Horwitz, C Rees, D R Clemmons

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 89 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Role of insulin-like growth factor binding proteins in mammary gland development.Journal of mammary gland biology and neoplasia · 2008
    Review
  9. Review
  10. The role of insulin-like growth factor binding proteins in development.Reviews in endocrine & metabolic disorders · 2005
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. How matrix metalloproteinases regulate cell behavior.Annual review of cell and developmental biology · 2001
    Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Y ImaiDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill 27599-7170, USA.
W H Busby
C E Smith
J B Clarke
A J Garmong
G D Horwitz
C Rees
D R Clemmons
University of North Carolina at Chapel Hill · USEndocrinology Research Center · RUMonsanto (United States) · US

Funding

MECHANISMS BY WHICH IGF-I STIMULATES SMOOTH MUSCLE CELLSR01HL056850 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CLEMMONS, DAVID ROBERT · 1996 to 2007
$2.5M
NHLBI NIH HHS HL-56850
6 · The paper itself

Abstract

IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs and cleavage makes it difficult to assess the role of intact IGFBP-5. To study the consequence of accumulation of intact IGFBP-5 in medium, we determined the cleavage site in IGFBP-5 and prepared a protease resistant mutant. Amino acid sequencing of purified IGFBP-5 fragments suggested Arg138-Arg139 as the primary cleavage site. Arg138-Arg139-->Asn138-Asn139 mutations were introduced to create protease-resistant IGFBP-5, which has the same affinity for IGF-I as the native protein. This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium. The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%. It also inhibited IGF-I stimulation of IRS-1 phosphorylation. In contrast, the same amount of native IGFBP-5 did not inhibit IGF-I actions. The significance of inhibitory effects of the protease resistant IGFBP-5 was further demonstrated in pSMC transfected with mutant or native IGFBP-5 cDNAs. The mutant IGFBP-5 accumulated in culture medium of transfected cells, while native IGFBP-5 was degraded into fragments, PSMC overexpressing the mutant IGFBP-5 also responded poorly to IGF-I compared with mock transfected cells. IGF-I (5 ng/ml) increased [35S]methionine incorporation into control cells by 36% above the basal level, but it did not significantly change (4%) in pSMC cultures that were producing the mutant IGFBP-5. In conclusion, the accumulation of protease-resistant IGFBP-5 in the medium was inhibitory to IGF-I actions on pSMC. This suggests that proteolysis can prevent IGFBP-5 from acting as an inhibitor of IGF-I-stimulated effects and that it serves as an important mechanism for regulating cellular responsiveness to IGF-I.

Indexed as

Amino Acid SequenceAnimalsAortaArginineAsparagineCell DivisionCells, CulturedCulture Media, ConditionedHumansInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 5Insulin-Like Growth Factor IMetalloendopeptidasesMuscle, Smooth, VascularMutagenesis, Site-DirectedPeptide FragmentsArginineAsparagineCulture Media, ConditionedInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 5Insulin-Like Growth Factor IMetalloendopeptidasesPeptide FragmentsRecombinant ProteinsThymidine

Identifiers

PMID9366575
PMCPMC508461
OpenAlexW2034967926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.